Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 15/20 | 0.62 |
| ▸ | HTR1A | P08908 | 3/20 | 0.62 |
| ▸ | DRD2 | P14416 | 3/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416326 | 1.00 | ABCB1 (0.62) | ABCB1HTR1ADRD2ABCG2TAAR1 | |
| SCHEMBL19900978 | 0.91 | ESR1 (0.56) | ABCB1HTR1ADRD2ABCG2TAAR1 | |
| SCHEMBL8702673 | 0.91 | CHRM2 (0.54) | ABCB1HTR1ADRD2ABCG2TAAR1 | |
| SCHEMBL19900980 | 0.89 | HDAC1 (0.56) | ABCB1HTR1ADRD2ABCG2TAAR1 | |
| SCHEMBL19900867 | 0.89 | HDAC1 (0.56) | ABCB1HTR1ADRD2ABCG2TAAR1 | |
| SCHEMBL19900804 | 0.89 | HDAC1 (0.56) | ABCB1HTR1ADRD2ABCG2TAAR1 | |
| SCHEMBL19900723 | 0.89 | HDAC1 (0.56) | ABCB1HTR1ADRD2ABCG2TAAR1 | |
| SCHEMBL19900758 | 0.89 | HDAC1 (0.56) | ABCB1HTR1ADRD2ABCG2TAAR1 | |
| SCHEMBL19900816 | 0.89 | HDAC1 (0.56) | ABCB1HTR1ADRD2ABCG2TAAR1 | |
| SCHEMBL8704118 | 0.87 | AKR1B1 (0.60) | ABCB1HTR1ADRD2ABCG2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200375949-A1 | BISPHENOL COMPOUNDS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-12-03 | — | — | US | claimed |
| CN-111807976-A | Novel method for preparing sarpogrelate hydrochloride | 深圳市道科思医药有限公司 | 2020-10-23 | — | — | CN | claimed |
| WO-2019104153-A1 | BISPHENOL COMPOUNDS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2019-05-31 | — | — | WO | claimed |
| CN-105906486-B | The synthetic method of Sarpogrelate intermediate 2 [2 (3 methoxyphenyl) ethyl] phenol | 安徽修制药有限公司 | 2018-04-20 | — | — | CN | claimed |
| CN-105906486-A | Synthetic method of sarpogrelate intermediate 2-[2-(3-methoxyphenyl)ethyl]phenol | 安徽禾益化学股份有限公司 | 2016-08-31 | — | — | CN | claimed |
| CN-103965063-B | Sarpogrelate hydrochloride new preparation process | Limited liability company of Kechuang institute of materia medica, Anhui (CN) | 2016-05-25 | — | — | CN | claimed |
| EP-3503879-B1 | COMPOSITION COMPRISING (A) A DUAL AGENT ACTING AS A 5-HT2A RECEPTOR ANTAGONIST AND CYP2D6 INHIBITOR AND (B) AN NMDA RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF DISEASES INVOLVING GLUCOSE | Exciva GmbH (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-20250216782-A1 | MASKING PROCESS USING SWITCHABLE POLYMER | TOKYO ELECTRON LTD (JP) | 2025-07-03 | — | — | US | disclosed |
| CN-117964462-A | Preparation method of 1-benzyloxy-2- [2- (3-methoxyphenyl) vinyl ] benzene | 苏州诚和医药化学有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | Exciva GmbH (DE) | 2022-10-25 | — | — | US | disclosed |
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | Exciva GmbH | 2021-07-29 | — | — | US | disclosed |
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | Exciva GmbH | 2021-07-29 | — | — | US | disclosed |
| CN-1245426-A | Composition containing diarylalkane derivative as effective component for treating or preventing pancreatitis | SANKYO CO (JP) | 2000-02-23 | — | — | CN | disclosed |
| EP-0958817-A1 | COMPOSITION CONTAINING DIARYLALKANE DERIVATIVE AS THE ACTIVE INGREDIENT FOR TREATING OR PREVENTING PANCREATITIS | SANKYO COMPANY LIMITED (JP) | 1999-11-24 | — | — | EP | disclosed |
| CN-1044365-C | Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory diseases and psychosis | SANKYO CO (JP) | 1999-07-28 | — | — | CN | disclosed |
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| CN-1102640-A | Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory and psychiatric disorders | SANKYO CO (JP) | 1995-05-17 | — | — | CN | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | HTR2A, HTR2C, CYP3A43 | ABCB1 50/4885HTR1A 24/4885DRD2 262/4885 |
| US-20200375949-A1 | BISPHENOL COMPOUNDS | RPP30, RPS10, RPS20 | ABCB1 2054/4885HTR1A 3326/4885DRD2 2596/4885 |
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | CYP21A2, CYP2C19, CYP2F1 | ABCB1 98/4885HTR1A 1544/4885DRD2 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.